Regulatory News
-
J&J's Ethicon Launches ProxiSure Suturing Device
8/21/2017
Ethicon, part of the Johnson & Johnson Medical Devices Companies, announced today the U.S. launch of the ProxiSure™ Suturing Device, an advanced laparoscopic suturing device featuring Ethicon endomechanical, suture and curved needle technologies.
-
Renovis Surgical's 3D-Printed Posterior Lumbar Interbody Fusion Systems Cleared By FDA
8/11/2017
Renovis Surgical Technologies, Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market posterior lumbar Tesera® porous titanium interbody fusion systems.
-
GE's SIGNA Premier 3.0 MRI Cleared By FDA
8/4/2017
GE Healthcare is proud to announce SIGNA Premier, a new wide bore 3.0T magnetic resonance imaging (MRI) system, is now available for sale in the U.S. SIGNA Premier is the result of a four-year collaboration with the National Football League (NFL) and research institutions around the world working to design new imaging tools, particularly to aid researchers in the detection of biomarkers for the potential diagnosis of mild Traumatic Brain Injury.
-
Medtronic's Avalus Surgical Aortic Valve Gains FDA, CE Mark Approval
8/2/2017
Medtronic plc recently announced CE (Conformité Européenne) mark and U.S. Food and Drug Administration (FDA) approval of its new Avalus pericardial aortic surgical valve for the treatment of aortic valve disease.
-
Immunalysis' Fentanyl Urine Drug Screening Test Cleared By FDA
7/31/2017
Immunalysis Corporation, a division of Alere Inc. (NYSE: ALR), today announced that its SEFRIA™ Fentanyl Urine Enzyme Immunoassay has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for the qualitative detection of fentanyl in urine.
-
Medtronic's CoreValve Evolut PRO TAVR Gains CE Mark, Launches In EU
7/31/2017
Medtronic plc recently announced CE (Conformité Européenne) mark and European launch of the CoreValve Evolut PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at intermediate, high or extreme risk for open heart surgery
-
Quantitative Insights' QuantX Advanced Computer-Aided Diagnosis Platform Earns FDA De Novo Approval
7/27/2017
Quantitative Insights, Inc. (QI) recently announced that it has received regulatory clearance (via De Novo classification) from the U.S. Food and Drug Administration (FDA) for its QuantX Advanced system, the industry’s first computer-aided diagnosis platform incorporating machine learning for the evaluation of breast abnormalities.
-
FDA Clears First Neonatal Magnetic Resonance Imaging Device
7/20/2017
Recently, the U.S. Food and Drug Administration cleared the first magnetic resonance imaging (MRI) device specifically for neonatal brain and head imaging in neonatal intensive care units (NICU).
-
FDA Clears Philips' Wearable Light Therapy Device For Psoriasis
7/13/2017
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Philips BlueControl wearable light therapy device to treat mild psoriasis.
-
Stryker's MultiGen 2 RF Generator Cleared BY FDA
7/11/2017
Stryker announced today that it has received FDA 510(k) clearance for its MultiGen 2 RF Generator. This product provides physicians with the efficiency, control and reliability they need when performing radiofrequency ablation, a minimally invasive procedure that can provide lasting relief to those suffering from facet joint pain.1